InnoCan Pharma (TSE:INNO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InnoCan Pharma has announced a significant regulatory milestone with the FDA setting a meeting to discuss the company’s LPT-CBD technology for chronic pain treatment. The technology promises a breakthrough in non-opioid pain management with a single monthly injection, which has shown promising results in preclinical trials. The FDA consultation will be crucial for InnoCan to begin human clinical trials and address the opioid crisis with this novel treatment.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.